Industry: Pharmaceuticals (See others in industry)
Address:| Date | FilingType | Incremental Cash | Link to Raw Filing | |||
|---|---|---|---|---|---|---|
| 2025-12-04 | New | $120,061,960 | $120,061,960 | Equity Only | 06b | SEC link |
| 2022-04-19 | Amended | $42,550,007 | $7,749,999 | Equity Only | 06b | SEC link |
| 2022-02-11 | New | $34,800,008 | $34,800,008 | Equity Only | 06b | SEC link |
| 2021-09-17 | New | $10,000,000 | $10,000,000 | Equity Only | 06b | SEC link |
| 2020-07-06 | New | $6,000,000 | $6,000,000 | Equity Only | 06b | SEC link |
| Name | Role |
|---|---|
| Nathaniel Brooks Horwitz | Director |
| Shelley Chu | Director |
| Milind Deshpande | Director |
| David Grayzel | Director |
| Andrew Hedin | Director |
| Lorence Kim | Director |
| Andrew Levin | Director |
| Christopher O'donnel | Director |
| Christopher O'donnell | Director |
| Jigar Raythatha | Director |
| Simon Read | Director |
| Joshua Resnick | Director |
| Patrick Trojer | Director, Executive |